Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

New $3.7 million non-dilutive federal funding extends total AP-SA02 program support to about $32.4 million as Phase 3 planning progresses.

Rhea-AI Summary

Armata Pharmaceuticals (ARMP) received an additional $3.7 million in non-dilutive funding from the U.S. Department of War to support Phase 3 development of its lead bacteriophage candidate AP-SA02 for complicated Staphylococcus aureus bacteremia (SAB).

The new commitment is the first funding earmarked specifically for Phase 3 execution under a previously awarded Department of War grant administered through MTEC and managed by NMRC–NAMD, with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. This raises total non-dilutive backing for AP-SA02 to approximately $32.4 million.

AP-SA02, a fixed multi-phage cocktail given adjunctively to antibiotics for SAB caused by MSSA or MRSA, holds QIDP, Fast Track, and Breakthrough Therapy designations from the FDA. Positive Phase 2a diSArm data were previously presented, and Armata plans to initiate a Phase 3 superiority study in the second half of 2026.

Positive

• $3.7 million in new non-dilutive Department of War funding for AP-SA02 Phase 3 activities
• Total non-dilutive DoW support for AP-SA02 increased to about $32.4 million
• AP-SA02 holds FDA QIDP, Fast Track, and Breakthrough Therapy designations
• Positive Phase 2a diSArm data previously highlighted in a late-breaking oral presentation at IDWeek 2025
• Company plans a Phase 3 superiority study in complicated SAB, expected to start in H2 2026

Negative

• None.

Argus 15 min delay 1 alert

+2.38% vs previous close $4.30 last price 0.0x rel. volume Open Argus

Details

Market Reaction – ARMP

$4.26 $5.03 Day Range

$159.88M Market Cap

On Sep 23, the day this news came out, the latest delayed price for ARMP is 2.38% above the previous close. The latest delayed price is $4.30.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

On Jul 20, the earlier $2.5 million DoW continuation award brought cumulative funding to $28.7 milli...

Analysis

On Jul 20, the earlier $2.5 million DoW continuation award brought cumulative funding to $28.7 million and supported Phase 3 readiness, making this reported increment a continuation of the same AP-SA02 award.

Key Figures

Additional DoW funding: $3.7 million Previously provided DoW funding: $28.7 million Anticipated Phase 3 study initiation: Second half of 2026

Additional DoW funding

$3.7 million

Additional non-dilutive funds for AP-SA02 Phase 3 development

Previously provided DoW funding

$28.7 million

Funding provided before this additional commitment

Anticipated Phase 3 study initiation

Second half of 2026

Planned AP-SA02 superiority study in complicated SAB

Previous Clinical trial Reports

2 past events · Latest: Jul 20

Same Type 2 events

1. Jul 20

   Phase 3 funding progress

   24h Move

   +12.2%

   Protocol submission, manufacturing runs and a $2.5 million continuation award brought total funding to $28.7 million.

2. May 01

   DoW funding tranche

   24h Move

   -15.4%

   Additional DoD funding supported AP-SA02 and brought cumulative award funding to $26.2 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bacteriophage, qidp, fast track designation, breakthrough therapy designation, +2 more

6 terms

bacteriophage medical

"pathogen-specific bacteriophage therapeutics"

A bacteriophage is a virus that infects and kills specific bacteria, acting like a precision tool that targets only certain bacterial strains. For investors, bacteriophage-based products matter because they represent an alternative to traditional antibiotics, potentially addressing drug-resistant infections and creating new markets in healthcare and agriculture; success or failure in development and regulation can sharply affect the value of companies working in this field.

qidp regulatory

"Qualified Infectious Disease Product (QIDP) designation"

A QIDP (Qualified Infectious Disease Product) is a regulatory designation for drugs or biologics that treat serious bacterial or fungal infections. It signals faster review and gives additional market protection after approval, like an extra patent-like time window, which can delay competitors — think of it as a temporary “no-competition” zone enforced by the regulator. For investors, QIDP status can speed a product to market and meaningfully enhance revenue potential and valuation.

fast track designation regulatory

"Fast Track designation"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

breakthrough therapy designation regulatory

"Breakthrough Therapy designation from the FDA"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

mssa medical

"methicillin-sensitive S. aureus ("MSSA")"

Methicillin-susceptible Staphylococcus aureus (MSSA) is a strain of the common bacterium Staphylococcus aureus that can be killed or controlled by methicillin-class antibiotics because it lacks the resistance mechanisms found in MRSA. It matters to investors because MSSA is a frequent target in clinical trials, diagnostics and hospital treatments; the size of the MSSA patient population and available therapies influence demand for antibiotics, diagnostics, medical devices and related healthcare products—like a common problem that responds to standard solutions.

mrsa medical

"methicillin-resistant S. aureus ("MRSA")"

MRSA is a type of common bacteria that has become resistant to many standard antibiotics, causing infections that are harder to treat. Think of it like a weed that no longer responds to the usual weedkiller; it raises the need for stronger medicines, longer hospital stays, and new products or procedures. For investors, MRSA affects healthcare costs, drug and diagnostic demand, regulatory scrutiny, and potential legal or reputational risks for providers and drugmakers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia

New commitment is incremental to previously announced DoW funding and expands total non-dilutive support for the AP-SA02 program to $32.4 million

LOS ANGELES, Sept. 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $3.7 million in non-dilutive funds from the U.S. Department of War ("DoW") to support activities associated with the Phase 3 development program for AP-SA02.

Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise Consortium ("MTEC") and managed by the Naval Medical Research Command ("NMRC") – Naval Advanced Medical Development ("NAMD") with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. This funding follows the $28.7 million previously provided, bringing cumulative non-dilutive DoW funding under the award to approximately $32.4 million and underscoring the U.S. government's continued interest in advancing the AP-SA02 program.

Armata's lead clinical candidate, AP-SA02, is being developed as an adjunctive treatment for complicated Staphylococcus aureus bacteremia ("SAB") caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). The additional funding will be used to support the Phase 3 clinical program for AP-SA02.

"The DoW has supported the AP-SA02 program through multiple stages of its development, and these new funds extend that support into Phase 3," said Dr. Deborah Birx, Chief Executive Officer of Armata.

"We believe the continued commitment of non-dilutive federal funding reflects the importance of developing new approaches to serious and difficult-to-treat bacterial infections, including antibiotic-resistant S. aureus. Complicated SAB remains associated with substantial morbidity and mortality in both military and civilian populations, underscoring the need for therapies that can complement existing antibiotics and improve outcomes for patients."

Dr. Birx continued, "We view this funding as the first commitment of DoW support for the Phase 3 program, and we intend to continue working closely with the DoW regarding potential additional support as the Phase 3 study advances. Our long-standing collaboration has helped us move the program from early clinical development toward a pivotal study, while providing meaningful non-dilutive capital to support its advancement."

About AP-SA02

Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated SAB caused by MSSA or MRSA. AP-SA02 has received Qualified Infectious Disease Product (QIDP) designation, Fast Track designation, and Breakthrough Therapy designation from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy ("BAT") compared to BAT alone (placebo) for the treatment of adults with complicated SAB. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, anticipated to initiate in the second half of 2026.

About Armata Pharmaceuticals, Inc.

Armata is a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.

Forward Looking Statements

This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. 

Media Contacts:

At Armata:

Pierre Kyme
ir@armatapharma.com
310-665-2928

Investor Relations:

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-receives-3-7-million-in-additional-non-dilutive-funding-from-us-department-of-war-to-support-advancement-of-ap-sa02-phase-3-development-302886960.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How will the additional $3.7 million in Department of War funding be used?

The additional $3.7 million in non-dilutive funds is earmarked to support activities associated with the Phase 3 clinical program for AP-SA02 in complicated Staphylococcus aureus bacteremia. The company describes it as the first commitment of Department of War support specifically for Phase 3 execution under the existing award.

What is AP-SA02 and for which patients is it being developed?

AP-SA02 is a fixed multi-phage cocktail that Armata is developing as an adjunctive treatment to standard antibiotics for adults with complicated Staphylococcus aureus bacteremia (SAB) caused by either methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA).

What were the key features of the Phase 1b/2a diSArm study of AP-SA02?

The diSArm trial (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study. It evaluated the safety, tolerability, and efficacy of intravenous AP-SA02 added to best available antibiotic therapy (BAT) compared to BAT plus placebo in adults with complicated SAB. Positive Phase 2a results were presented in a late-breaking oral session at IDWeek 2025.

When does Armata plan to start the Phase 3 study of AP-SA02?

The company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, which is anticipated to initiate in the second half of 2026.

What broader pipeline and capabilities does Armata highlight beyond AP-SA02?

Armata describes itself as a late clinical-stage biotechnology company developing a broad pipeline of natural and synthetic bacteriophage candidates targeting Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company notes in-house, phage-specific cGMP manufacturing capabilities to support full commercialization of its phage therapies.